Thompson Jaye

VP Clinical Affairs Thompson Jaye bought 1,000 shares of GLSI at $12.91 on 2024-11-21; stock now -31.4% from 52-week high.

Thompson Jaye, VP of Clinical Regulatory Affairs at Greenwich LifeSciences, purchased 1,000 shares at $12.91, bringing his holdings to 264,148 shares. The purchase occurred when the stock was trading well below its 52-week high of $20.32 (now -31.4% from peak), though it has gained 3.3% over the past 30 days. At the same-ticker level, Jaye's prior 5 purchases at GLSI show mixed timing outcomes: 3 of the 5 prior buys resulted in positive 90-day returns. The company remains unprofitable, posting a net loss of $-2.7M in its most recent full fiscal year. The modest purchase size relative to his large existing position (0.4% increase from 263.1K to 264.1K shares) offers limited directional signal on executive sentiment.

GLSI VP Thompson Jaye bought 800 shares at $13.85 on 2024-08-12; stock now $14.44, down -28.9% from 52-week high amid unprofitability.

Thompson Jaye, VP Clinical Reg Affairs, purchased 800 shares for $11,080.00 on 2024-08-12, increasing holdings to 263.1K shares. The transaction occurred at $13.85 while the stock now trades at $14.44, a modest recovery, though the security remains -28.9% below its 52-week high of $20.32. Within the same-ticker history at GLSI, Jaye has executed 5 prior trades; of the 3 completed 90-day measurements, 2 showed positive returns (60.0% win rate), but the two most recent buys in August and July 2024 are tracking negative at the 30-day mark (-7.5% and -13.1% respectively). Against a backdrop of company unprofitability ($-2,606,682.00 net income for the full year), the continued purchasing by a clinical executive warrants attention to whether insider acquisition reflects conviction in pipeline or regulatory progress, or instead reflects opportunistic bottom-fishing during a depressed market environment.

VP Clinical Reg Affairs buys 1,000 GLSI shares at $15.15; stock down 34.7% from 52-week high, company unprofitable

Thompson Jaye purchased 1,000 shares at $15.15 on 2024-08-02, adding to holdings of 262.3K shares. The stock has declined significantly since the transaction, trading at $13.26 (−34.7% from the 52-week high of $20.32) and −20.6% over 30 days. At this specific ticker, his prior timing was mixed: 2 of 4 prior measurable buys achieved positive 90-day returns, but this purchase has occurred in a deteriorating market context—the company reported negative net income of $-2.5M for its most recent fiscal year. The recent buy on 2024-07-18 outcome remains unmeasurable, so current conviction-level assessment at GLSI is incomplete.

VP Clinical Reg Affairs Thompson Jaye bought 1,000 shares of GLSI at $16.00; stock now 23.3% below 52-week high, company unprofitable.

Thompson Jaye purchased 1,000 shares at $16.00, increasing holdings from 260,348 to 261,348 shares—a modest 0.4% addition. The purchase occurred after a -4.2% decline over the prior 30 days, though the stock remains 30-day positive at +18.6% over 90 days. At GLSI specifically, his five prior buys show a mixed 40% hit rate at the 90-day mark: two trades generated positive 90-day returns (39.7% and 23.0%), while three experienced losses ranging from -4.5% to -23.2%. The company reported negative net income of $-2.5M and carries a $200.8M market cap, indicating unprofitability. The $16.00 transaction price sits between the 52-week low of $7.77 and the current price of $15.59, placing it in the lower half of the annual range but not at extreme lows.